AU2009329814B2 - Osteoarthritis treatment - Google Patents

Osteoarthritis treatment Download PDF

Info

Publication number
AU2009329814B2
AU2009329814B2 AU2009329814A AU2009329814A AU2009329814B2 AU 2009329814 B2 AU2009329814 B2 AU 2009329814B2 AU 2009329814 A AU2009329814 A AU 2009329814A AU 2009329814 A AU2009329814 A AU 2009329814A AU 2009329814 B2 AU2009329814 B2 AU 2009329814B2
Authority
AU
Australia
Prior art keywords
csf
seq
antibody
ser
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009329814A
Other languages
English (en)
Other versions
AU2009329814A1 (en
Inventor
Andrew David Cook
John Allan Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Melbourne
Original Assignee
University of Melbourne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42286786&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009329814(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Melbourne filed Critical University of Melbourne
Publication of AU2009329814A1 publication Critical patent/AU2009329814A1/en
Application granted granted Critical
Publication of AU2009329814B2 publication Critical patent/AU2009329814B2/en
Priority to AU2015224416A priority Critical patent/AU2015224416B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Virology (AREA)
  • Glass Compositions (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Polarising Elements (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2009329814A 2008-12-22 2009-12-21 Osteoarthritis treatment Active AU2009329814B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2015224416A AU2015224416B2 (en) 2008-12-22 2015-09-09 Osteoarthritis treatment

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13967908P 2008-12-22 2008-12-22
US61/139,679 2008-12-22
US16448609P 2009-03-30 2009-03-30
US61/164,486 2009-03-30
PCT/AU2009/001672 WO2010071924A1 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2015224416A Division AU2015224416B2 (en) 2008-12-22 2015-09-09 Osteoarthritis treatment

Publications (2)

Publication Number Publication Date
AU2009329814A1 AU2009329814A1 (en) 2010-07-01
AU2009329814B2 true AU2009329814B2 (en) 2015-06-18

Family

ID=42286786

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009329814A Active AU2009329814B2 (en) 2008-12-22 2009-12-21 Osteoarthritis treatment

Country Status (19)

Country Link
US (4) US9243061B2 (https=)
EP (2) EP3056217B1 (https=)
JP (3) JP5727379B2 (https=)
KR (2) KR101898982B1 (https=)
CN (2) CN102271705A (https=)
AU (1) AU2009329814B2 (https=)
BR (1) BRPI0918356B1 (https=)
CA (1) CA2746827C (https=)
CY (1) CY1117698T1 (https=)
DK (1) DK2376121T4 (https=)
ES (2) ES2572368T5 (https=)
HK (1) HK1226938A1 (https=)
HR (1) HRP20160577T4 (https=)
HU (1) HUE028615T2 (https=)
PL (1) PL2376121T5 (https=)
RU (2) RU2712273C2 (https=)
SI (2) SI2376121T1 (https=)
SM (1) SMT201600156B (https=)
WO (1) WO2010071924A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
EP3345923A1 (en) 2012-09-20 2018-07-11 MorphoSys AG Treatment for rheumatoid arthritis with anti-gm-csf antibody
DE102013222200A1 (de) * 2013-10-31 2015-08-27 Osram Opto Semiconductors Gmbh Elektronisches Bauelement und Verfahren zum Herstellen eines elektronischen Bauelements
IL301622A (en) * 2017-08-14 2023-05-01 Zynerba Pharmaceuticals Inc Methods for treating degenerative joint disease with cannabidiol gel through the skin
WO2020104833A1 (en) * 2018-11-19 2020-05-28 4P-Pharma Composition and methods for regulating chondrocyte proliferation and increasing of cartilage matrix production
CN110075304B (zh) * 2019-05-29 2020-02-11 四川大学华西医院 一种治疗骨关节炎的药物组合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010126A1 (en) * 2000-05-08 2002-01-24 John Hamilton Method of treatment and agents useful for same
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2007110631A1 (en) * 2006-03-27 2007-10-04 Medimmune Limited Binding member for gm-csf receptor
WO2008064321A2 (en) * 2006-11-21 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU630496B2 (en) 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
WO1991002063A1 (en) 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
WO1994009149A1 (en) 1990-08-10 1994-04-28 Amrad Corporation Limited Monoclonal antibody
CA2149881A1 (en) 1992-11-19 1994-05-26 Paul T. Jubinsky Antibodies for gm-csf receptor and uses thereof
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
AUPP525198A0 (en) 1998-08-13 1998-09-03 Medvet Science Pty. Ltd. Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
EP1442132A2 (en) * 2001-10-26 2004-08-04 Novartis AG Methods for the treatment of osteoarthritis and compositions thereof
US7381801B2 (en) 2002-02-13 2008-06-03 Ludwig Institute For Cancer Research Chimerized GM-CSF antibodies
US20040241755A1 (en) * 2003-06-02 2004-12-02 Pfizer Inc. Human cell assay to determine effect of sample compounds on Col2 enhancer expression
BRPI0506679A (pt) 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
CN1960758B (zh) * 2004-03-31 2014-10-22 中外制药株式会社 关节炎的治疗剂或预防剂
EP1593690B1 (en) 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
EP1782074A2 (en) * 2004-08-18 2007-05-09 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Biomarkers for osteoarthritis
US20060040258A1 (en) 2004-08-23 2006-02-23 Huiyan Guo Water-soluble conjugates and methods of preparation
EP2468774A3 (en) 2005-04-18 2013-01-02 Amgen Research (Munich) GmbH Antibody neutralizers of human granulocyte macrophage colony stimulating factor
EP3620171B1 (en) * 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf antibodies and uses therefor
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
EA200801166A1 (ru) * 2005-12-01 2008-12-30 Домантис Лимитед Форматы конкурентного доменного антитела, которые связываются с рецептором интерлейкина 1 первого типа
US7741273B2 (en) 2006-04-13 2010-06-22 Warsaw Orthopedic, Inc. Drug depot implant designs
WO2008080134A2 (en) * 2006-12-22 2008-07-03 Rigel Pharmaceuticals, Inc. 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009042854A1 (en) * 2007-09-26 2009-04-02 Musculoskeletal Research Llc Ion-channel regulator compositions and methods of using same
EP2217626A4 (en) 2007-11-12 2011-06-22 Crc For Asthma And Airways Ltd EPITOP FOR NEUTRALIZING ANTIBODIES
PE20091420A1 (es) 2007-11-13 2009-10-17 Evec Inc ANTICUERPOS MONOCLONALES ANTI hGM-CSF
US20100040630A1 (en) 2008-03-24 2010-02-18 Aake Elden Methods and compositions for treating bone loss
NZ588850A (en) 2008-04-28 2012-12-21 Kalobios Pharmaceuticals Inc Antibodies to granulocyte-macrophage colony-stimulating factor
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
EP3056217B1 (en) * 2008-12-22 2021-06-30 The University of Melbourne Osteoarthritis treatment
CN102459340A (zh) 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010126A1 (en) * 2000-05-08 2002-01-24 John Hamilton Method of treatment and agents useful for same
WO2007092939A2 (en) * 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
WO2007110631A1 (en) * 2006-03-27 2007-10-04 Medimmune Limited Binding member for gm-csf receptor
WO2008064321A2 (en) * 2006-11-21 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a gm-csf antagonist
WO2008141391A1 (en) * 2007-05-23 2008-11-27 Crc For Asthma And Airways Ltd Neutralizing antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN HOLTON, J. et al Arthritis Research, Vol. 3, No. 5, page 293-298. 11 June 2001. *

Also Published As

Publication number Publication date
BRPI0918356B1 (pt) 2022-03-08
HRP20160577T4 (hr) 2021-08-20
SI2376121T2 (sl) 2021-11-30
RU2712273C2 (ru) 2020-01-28
AU2009329814A1 (en) 2010-07-01
EP2376121A1 (en) 2011-10-19
JP5727379B2 (ja) 2015-06-03
CY1117698T1 (el) 2017-05-17
ES2572368T5 (es) 2021-12-16
JP2012512815A (ja) 2012-06-07
EP2376121B2 (en) 2021-06-09
KR20170128630A (ko) 2017-11-22
PL2376121T3 (pl) 2016-12-30
CN106397591A (zh) 2017-02-15
US9243061B2 (en) 2016-01-26
US20200247895A1 (en) 2020-08-06
EP2376121B1 (en) 2016-03-09
CA2746827C (en) 2018-01-23
EP3056217A1 (en) 2016-08-17
US20160185868A1 (en) 2016-06-30
HRP20160577T1 (hr) 2016-07-29
RU2016102339A (ru) 2018-11-21
ES2886063T3 (es) 2021-12-16
KR20110128273A (ko) 2011-11-29
US20120003234A1 (en) 2012-01-05
JP2015143233A (ja) 2015-08-06
PL2376121T5 (pl) 2021-09-27
JP2017200933A (ja) 2017-11-09
HK1226938A1 (en) 2017-10-13
KR101898982B1 (ko) 2018-09-14
DK2376121T4 (da) 2021-08-16
DK2376121T3 (en) 2016-05-30
HUE028615T2 (en) 2016-12-28
EP2376121A4 (en) 2013-04-03
JP6458086B2 (ja) 2019-01-23
KR101799264B1 (ko) 2017-11-20
BRPI0918356A2 (pt) 2020-10-06
SI2376121T1 (sl) 2016-07-29
US20180066062A1 (en) 2018-03-08
RU2011127334A (ru) 2013-01-27
EP3056217B1 (en) 2021-06-30
RU2016102339A3 (https=) 2019-07-29
WO2010071924A1 (en) 2010-07-01
CA2746827A1 (en) 2010-07-01
CN102271705A (zh) 2011-12-07
SMT201600156B (it) 2016-08-31
ES2572368T3 (es) 2016-05-31

Similar Documents

Publication Publication Date Title
US20200247895A1 (en) Osteoarthritis treatment
EP2387418B1 (en) Pain treatment
US20140243506A1 (en) Antagonists of il17c for the treatment of inflammatory disorders
AU2015224416B2 (en) Osteoarthritis treatment
HK1162336A (zh) 骨关节炎治疗

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)